City of Hope

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Acute myeloid leukaemia1 trial
• Bladder cancer1 trial
• Chronic myeloid leukaemia1 trial
• Diffuse large B-cell lymphoma1 trial
• Follicular lymphoma1 trial
• Kidney cancer1 trial
• Myelodysplastic syndromes1 trial
• Myeloproliferative neoplasms1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial

Phase

• Phase 1/24 trials
• Phase 12 trials
• Phase 22 trials
• Phase 31 trial
• Phase 41 trial

Status

• Recruiting7 trials
• Active, not recruiting2 trials
• Terminated1 trial

Lead sponsor

• Brigham and Women's Hospital1 trial
• CG Oncology, Inc.1 trial
• Geron Corporation1 trial
• Hemavant Sciences GmbH1 trial
• ImmunityBio, Inc.1 trial
• and 5 more

Running trials

• Recruiting

  A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

  NCT07735533· Phase 1/2· Umoja Biopharma· Source

  Contact: Azra Borogovac, MD, MS

• Recruiting

  Statins to Prevent Cancer Associated Blood Clots

  NCT07303816· Phase 4· Brigham and Women's Hospital· Source

  Contact: Faizi Jamal, MD

• Recruiting

  A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

  NCT07157033· Phase 1/2· Xerient Pharma· Source

  Contact: Xanthia Fajardo

• Recruiting

  CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

  NCT07322094· Phase 1/2· TORL Biotherapeutics, LLC· Source

  Contact: Caroline Labib, PharmD

• Recruiting

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· Phase 3· ImmunityBio, Inc.· Source

  Contact: Lee Hong, MD

• Recruiting

  Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

  NCT06567743· Phase 2· CG Oncology, Inc.· Source

  Contact: Cory Hugen, MD

• Active, not recruiting

  Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

  NCT06053658· Phase 2· M.D. Anderson Cancer Center· Source

• Recruiting

  First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

  NCT06043817· Phase 1/2· Pierre Fabre Medicament· Source

  Contact: Adele De MASSON, clinical development director, MD, PhD

• Active, not recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

  NCT05371964· Phase 1· Geron Corporation· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Bladder cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting

Closed trials

• Terminated

  A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

  NCT02841540· Phase 1· Hemavant Sciences GmbH· Source